JP2022548690A5 - - Google Patents

Info

Publication number
JP2022548690A5
JP2022548690A5 JP2022517374A JP2022517374A JP2022548690A5 JP 2022548690 A5 JP2022548690 A5 JP 2022548690A5 JP 2022517374 A JP2022517374 A JP 2022517374A JP 2022517374 A JP2022517374 A JP 2022517374A JP 2022548690 A5 JP2022548690 A5 JP 2022548690A5
Authority
JP
Japan
Prior art keywords
difluoromethyl
thiadiazole
indazole
amino
sulfonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2022517374A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022548690A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/051486 external-priority patent/WO2021055744A1/en
Publication of JP2022548690A publication Critical patent/JP2022548690A/ja
Publication of JP2022548690A5 publication Critical patent/JP2022548690A5/ja
Priority to JP2024193094A priority Critical patent/JP7781244B2/ja
Ceased legal-status Critical Current

Links

JP2022517374A 2019-09-20 2020-09-18 Parg阻害剤としての4-置換インドールおよびインダゾールスルホンアミド誘導体 Ceased JP2022548690A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024193094A JP7781244B2 (ja) 2019-09-20 2024-11-01 Parg阻害剤としての4-置換インドールおよびインダゾールスルホンアミド誘導体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962903438P 2019-09-20 2019-09-20
US62/903,438 2019-09-20
PCT/US2020/051486 WO2021055744A1 (en) 2019-09-20 2020-09-18 4-substituted indole and indazole sulfonamido derivatives as parg inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024193094A Division JP7781244B2 (ja) 2019-09-20 2024-11-01 Parg阻害剤としての4-置換インドールおよびインダゾールスルホンアミド誘導体

Publications (2)

Publication Number Publication Date
JP2022548690A JP2022548690A (ja) 2022-11-21
JP2022548690A5 true JP2022548690A5 (enExample) 2023-09-20

Family

ID=72744866

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022517374A Ceased JP2022548690A (ja) 2019-09-20 2020-09-18 Parg阻害剤としての4-置換インドールおよびインダゾールスルホンアミド誘導体
JP2024193094A Active JP7781244B2 (ja) 2019-09-20 2024-11-01 Parg阻害剤としての4-置換インドールおよびインダゾールスルホンアミド誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024193094A Active JP7781244B2 (ja) 2019-09-20 2024-11-01 Parg阻害剤としての4-置換インドールおよびインダゾールスルホンアミド誘導体

Country Status (16)

Country Link
US (1) US20220389003A1 (enExample)
EP (1) EP4031249B1 (enExample)
JP (2) JP2022548690A (enExample)
KR (1) KR20220066922A (enExample)
CN (1) CN114555593A (enExample)
AU (1) AU2020348489B2 (enExample)
BR (1) BR112022004624A2 (enExample)
CA (1) CA3147493A1 (enExample)
DK (1) DK4031249T3 (enExample)
FI (1) FI4031249T3 (enExample)
IL (1) IL291436B1 (enExample)
LT (1) LT4031249T (enExample)
MX (1) MX2022003276A (enExample)
PT (1) PT4031249T (enExample)
TW (1) TWI873187B (enExample)
WO (1) WO2021055744A1 (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41179A (fr) 2014-12-19 2017-10-24 Cancer Research Tech Ltd Composés inhibiteurs de parg
US20250002491A1 (en) 2021-10-04 2025-01-02 Forx Therapeutics Ag N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer
CA3225500A1 (en) 2021-10-04 2023-04-13 Ulrich Luecking Parg inhibitory compounds
IL311851A (en) * 2021-10-04 2024-05-01 Forx Therapeutics Ag PARG inhibitory compounds
CA3251360A1 (en) 2022-02-14 2023-08-17 Arase Therapeutics Inc. PARG INHIBITORS
EP4488275A4 (en) * 2022-03-04 2025-07-23 Shanghai Yingli Pharm Co Ltd COMPOUND CONTAINING A FIVE-MEMBERED HETEROAROMATIC RING STRUCTURE, PHARMACEUTICAL COMPOSITION AND USE THEREOF
WO2023175184A1 (en) 2022-03-17 2023-09-21 Forx Therapeutics Ag 2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer
WO2023175185A1 (en) 2022-03-17 2023-09-21 Forx Therapeutics Ag 2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer
PL4496795T3 (pl) * 2022-03-23 2026-07-20 Ideaya Biosciences, Inc. Związki indazolowe podstawione piperazyną jako inhibitory parg
IL316261A (en) 2022-04-28 2024-12-01 Danatlas Pharmaceuticals Co Ltd Tricyclic and heterocyclic derivatives, preparations and uses thereof
TW202409036A (zh) 2022-05-17 2024-03-01 美商858療法股份有限公司 Parg抑制劑
TWI878939B (zh) * 2022-06-29 2025-04-01 大陸商杭州聖域生物醫藥科技有限公司 五元並六元含氮化物、其中間體、製備方法和應用
AU2023310489A1 (en) * 2022-07-19 2025-02-13 Evopoint Biosciences Co., Ltd. Sulfur-containing heteroaromatic ring compound, pharmaceutical composition thereof, and use thereof
EP4311829A1 (en) 2022-07-28 2024-01-31 Nodus Oncology Limited Substituted bicyclic heteroaryl sulfonamide derivatives for the treatment of cancer
IL320031A (en) 2022-10-03 2025-06-01 Forx Therapeutics Ag Parg inhibitory compound
CN120051465A (zh) * 2022-10-13 2025-05-27 韩美药品株式会社 用于抑制yap-tead交互作用的新颖杂双环化合物及包含其的药学组成物
EP4646208A1 (en) 2023-01-06 2025-11-12 Ideaya Biosciences, Inc. Treatment of er+ breast cancer comprising homologous recombination deficiency using parg inhibitor
WO2024173234A1 (en) * 2023-02-13 2024-08-22 Arase Therapeutics Inc. Inhibitors of parg
WO2024173530A1 (en) * 2023-02-14 2024-08-22 Ideaya Biosciences, Inc. Heteroaryl-substituted pyrazolo/imidazo pyridine compounds
WO2024173524A1 (en) * 2023-02-14 2024-08-22 Ideaya Biosciences, Inc. Heteroaryl-substituted benzimidazole compounds
WO2024173453A1 (en) * 2023-02-14 2024-08-22 Ideaya Biosciences, Inc. Heteroaryl-substituted imidazopyridine compounds
WO2024173514A1 (en) * 2023-02-14 2024-08-22 Ideaya Biosciences, Inc. Amide and ester-substituted imidazopyridine compounds
WO2024209035A1 (en) 2023-04-05 2024-10-10 Forx Therapeutics Ag Parg inhibitory compounds
AU2024253809A1 (en) 2023-04-05 2025-10-16 Ideaya Biosciences, Inc. Combination therapy comprising a parg inhibitor and a topoisomerase inhibitor for treating cancer
CN121002021A (zh) * 2023-04-27 2025-11-21 北京丹擎医药科技有限公司 三环杂环衍生物及其组合物和应用
WO2024254990A1 (zh) 2023-06-16 2024-12-19 上海璎黎药业有限公司 一种杂芳环结构化合物、其药物组合物及应用
WO2025046148A1 (en) 2023-09-01 2025-03-06 Forx Therapeutics Ag Novel parg inhibitors
WO2025064750A1 (en) 2023-09-20 2025-03-27 Ideaya Biosciences, Inc. Combination therapy with a parg inhibitor
TW202528308A (zh) * 2023-09-20 2025-07-16 美商愛德亞生物科學公司 Parg抑制劑
WO2025072544A1 (en) * 2023-09-27 2025-04-03 Ideaya Biosciences, Inc. Sulfonamino indazole compounds as inhibitors of parg
WO2025067464A1 (zh) * 2023-09-28 2025-04-03 杭州圣域生物医药科技有限公司 杂芳基化合物、其中间体、制备方法和应用
KR20260084620A (ko) 2023-10-03 2026-06-05 포알엑스 테라퓨틱스 아게 Parg 억제 화합물
WO2025082231A1 (zh) * 2023-10-20 2025-04-24 上海璎黎药业有限公司 一种杂芳环磺酰胺结构化合物、其药物组合物及应用
WO2025087941A1 (en) 2023-10-23 2025-05-01 Universite De Geneve Parg inhibitors in combination with parp inhibitors and uses thereof
CN122249439A (zh) 2023-10-26 2026-06-19 上海齐鲁制药研究中心有限公司 Parg抑制剂
WO2025087274A1 (zh) 2023-10-27 2025-05-01 浙江海正药业股份有限公司 氮杂双环类衍生物及其制备方法和用途
WO2025093755A1 (en) 2023-11-01 2025-05-08 Forx Therapeutics Ag Novel parc inhibitors
WO2025098445A1 (zh) * 2023-11-07 2025-05-15 南京同诺康医药科技有限公司 Parg抑制剂及其制备方法和用途
WO2025108225A1 (zh) * 2023-11-20 2025-05-30 上海复星医药(集团)股份有限公司 作为parg抑制剂的含氮三环衍生物
WO2025111339A1 (en) * 2023-11-21 2025-05-30 858 Therapeutics, Inc. Treatment of cancer with a parg inhibitor
AR134429A1 (es) * 2023-11-22 2026-01-14 858 Therapeutics Inc Inhibidores de parg
WO2025133396A1 (en) 2023-12-22 2025-06-26 Forx Therapeutics Ag Novel bicyclo heteroaryl parg inhibitors
WO2025133191A1 (en) * 2023-12-22 2025-06-26 Genecode Novel sulfonamides or sulfones and their use as neuroprotective and/or neurorestorative agents
WO2025229549A1 (en) * 2024-04-30 2025-11-06 Satyarx Pharma Innovations Pvt Ltd Novel heterocyclic compounds as inhibitors of parg
CN118459452B (zh) * 2024-07-10 2024-10-25 苏州国匡医药科技有限公司 一种多聚adp核糖水解酶抑制剂及其应用
WO2026022150A1 (en) 2024-07-22 2026-01-29 Forx Therapeutics Ag Parg inhibitory compounds
TW202610628A (zh) * 2024-07-29 2026-03-16 大陸商海思科醫藥集團股份有限公司 磺醯胺化合物及其在醫藥上的應用
WO2026032385A1 (zh) * 2024-08-07 2026-02-12 上海亚虹医药科技有限公司 多聚adp核糖水解酶抑制剂及其医药用途
WO2026040953A1 (zh) * 2024-08-19 2026-02-26 上海和誉生物医药科技有限公司 一种多环parg抑制剂和其应用
WO2026042050A1 (en) * 2024-08-23 2026-02-26 Recursion Pharmaceuticals, Inc. Novel compounds and uses thereof
WO2026060261A1 (en) * 2024-09-13 2026-03-19 Equator Therapeutics, Inc. Compositions and methods for treating metabolic disorders
WO2026062066A1 (en) 2024-09-17 2026-03-26 Forx Therapeutics Ag Compounds inducing parg degradation

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
CA2242425C (en) 1996-02-13 2006-07-18 Zeneca Limited Quinazoline derivatives as vegf inhibitors
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
EE05345B1 (et) 1999-02-10 2010-10-15 Astrazeneca Ab Kinasoliini derivaadid angiogeneesi inhibiitoritena
BR0111230A (pt) 2000-05-31 2003-06-10 Astrazeneca Ab Composto, e, uso e processo para a preparação do mesmo
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
KR20030014425A (ko) 2000-07-07 2003-02-17 앤지오젠 파마슈티칼스 리미티드 혈관 손상제인 콜치놀 유도체
EE200300015A (et) 2000-07-07 2004-10-15 Angiogene Pharmaceuticals Limited Kolhinooli derivaadid kui angiogeneesi inhibiitorid
CA2834101A1 (en) * 2011-01-07 2012-07-12 Taiho Pharmaceutical Co., Ltd. Novel indole or indazole derivative or salt thereof
MA41140A (fr) * 2014-12-12 2017-10-17 Cancer Research Tech Ltd Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg
MA41179A (fr) * 2014-12-19 2017-10-24 Cancer Research Tech Ltd Composés inhibiteurs de parg
AU2018352695A1 (en) * 2017-10-19 2020-05-28 Effector Therapeutics, Inc. Benzimidazole-indole inhibitors of Mnk1 and Mnk2
PT3870575T (pt) * 2018-10-25 2023-05-12 Viiv Healthcare Uk No 5 Ltd Inibidores da replicação do vírus da imunodeficiência humana
PL4496795T3 (pl) * 2022-03-23 2026-07-20 Ideaya Biosciences, Inc. Związki indazolowe podstawione piperazyną jako inhibitory parg

Similar Documents

Publication Publication Date Title
JP2025016684A5 (enExample)
US10660877B2 (en) Pyridyl substituted indole compounds
KR101949624B1 (ko) Tank-결합 키나제 억제제 화합물로서 유용한 아미노트리아진 유도체
CN115397821A (zh) 含有与bcl6靶向部分连接的e3泛素连接酶结合部分的双官能分子
IL295799A (en) Trophomyosin receptor kinase (trk) degradation compounds and methods of use
JP2025540958A (ja) 蕁麻疹の治療のための野生型c-kitキナーゼ阻害剤としてのN-フェニル-ピラゾロ[1,5-A]ピリジン-3-カルボキサミド誘導体
TW201827428A (zh) 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JP2018524343A5 (enExample)
JP2019523233A5 (enExample)
JP2014062093A5 (enExample)
AU2021242143B2 (en) Aminopyrimidine derivatives and their use as Aryl hydrocarbon receptor modulators
KR20050096956A (ko) 피라졸 유도체
RU2015144485A (ru) Геминально-замещенные цианоэтилпиразолопиридоны в качестве ингибиторов janus киназ
FI3911631T3 (fi) Uusia substituoituja sulfonyyliureajohdannaisia
JP2016514709A5 (enExample)
US20060189591A1 (en) Five-membered heterocyclic derivative
JPWO2006004027A1 (ja) ピラゾール誘導体
JPWO2020203609A5 (enExample)
WO2020203609A1 (ja) 掻痒を治療するためのt型カルシウムチャネル阻害剤の使用
JP2012517981A (ja) Nk3受容体アンタゴニストとしてのピロリジン誘導体
JPWO2006014005A1 (ja) ピラゾール誘導体
HK40086197A (en) Aminopyrimidine derivatives and their use as aryl hydrocarbon receptor modulators
RU2021113492A (ru) Новые аминопиримидонилпиперидинильные производные, способ их получения и содержащие их фармацевтические композиции
RU2024111196A (ru) Соединения пиразоло[3,4-b]пиридина для лечения аутоиммунного заболевания
TH2201002013A (th) สารประกอบไบไซคลิกและการใช้งานของพวกมัน